TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Subjects Developing Inhibitors Against Factor IX (FIX)
Endpoint domain: Adverse events/effects
Primary endpoint: Apo B48 plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of scrub typhus
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of spotted fever
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of murine typhus
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of bone marrow stromal cells (BMSC)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse drug event
Endpoint domain: Adverse events/effects
Primary endpoint: Minimal luminal size for aorta and ileofemoral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical Global Impression (CGI)-Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma concentrations of minocycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ELF concentrations of minocycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar Macrophage concentrations of minocycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Infant Participants With Medically Assessed, RSV-associated Lower Respiratory Tract Illnesses (LRTIs) of Any Severity and RSV-associated Severe LRTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Infant Participants With at Least One Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Infant Participants With at Least One Adverse Event (AE) Leading to Study Withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: dysphagia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and/or rates of subjects with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration versus time curve from time 0 to the last timepoint with quantifiable concentration [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of anti-carbamylated protein antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: size of healing areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: speed of healing areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area and depth of color of black stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of vaccinees that seroconverts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Composite outcome of maternal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in proptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Improvement in activity of Graves' ophthalmopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean volume per void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Shannon diversity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Behavior-Negative Verbalizations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Classroom Behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cumulative Anti Rotavirus Serum Immunoglobulin A (IgA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ICIQ-UI SF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 hour pad weight test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of lymph nodes in postoperative specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Peritumoral Enhancement/Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major adverse cardiac and cerebral events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline of Pulmonary Artery Systolic Pressure (PASP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in C-peptide during Mixed Meal Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Tryptophan Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot Flash Frequency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in Framingham risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV 3-D volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of Nasolabial folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prescribing rate of antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative urinary bladder catheterization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants with a Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Device/System Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Successful Pulmonary Artery Pressure Data Transmissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with frailty identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty's severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With an SLE Responder Index 4 (SRI-4) Response at Day 210
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Safety of Abatacept
Endpoint domain: Adverse events/effects
Primary endpoint: Participant Engagement and Adherence to Intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Intervention Participants Satisfaction with Peer Health Coach Intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of High Resolution MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of High Resolution MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Combined Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean GELP score at week 24
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence and types of adverse events and adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory values and vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of anti-KHK4827 antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in intention on performing physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cardiovascular and cardiorespiratory coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Digit Span Total Raw Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spatial Span Total Raw Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavior Rating Inventory of Executive Function (BRIEF) - Working Memory Subscale Raw Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Re-Bleed rate after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TUG-Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total aneurysmal occlusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cumulative Incidence of Ototoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: HIV-free survival at 18 - 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in vitamin D3 status at blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in vitamin Interleukin-6 status at blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in vitamin TumorNecrosisFactor-alfa status at blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in cognitive test Quality of life Short Form-36 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in cognitive test Chalder Fatigue Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in functional test Up&Go
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Biochemical parameters (Netrin-1 and Unc5b)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Freedom at 2 Hours Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of Niaspan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sodium mass balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evidence of change in neurotoxicity based on chore
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degree of drug craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Type and severity of stimulant withdrawal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Mean oxidative balance ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA level of IGF-1Ea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of kinematic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periprosthetic bone remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral stem stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection and distinction of paediatric liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean number of migraine episodes per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Recall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma catecholamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lowering portal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CMV Infection Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: composite molecular and physiologic effect on cellular homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infarct size 5 days post MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bioresistant properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Level of Acetaminophen-cysteine (APAP-Cys) Protein Adducts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of neurologic injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inter-individual pharmacokinetic variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion changes to the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of JNJ-73763989
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Assessment (PGA) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Full or partial return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Point accuracy of the continuous glucose monitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Efficacy of acetaminophen by Verbal Numerical Rating Scale (VNRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of acetaminophen by Visual Analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of acetaminophen by total morphine equivalent daily dose (MEDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of PCR confirmed cases among pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: sensitivity of multisequence MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in SBP and DBP at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in the Profile of Epidemiologically-Important Organism
Endpoint domain: Adverse events/effects
Primary endpoint: change in Positive and Negative Syndrome Scale (PANSS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in working memory accuracy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in working memory reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days to regain birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cellular composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline to Day 4, Day 8 and Day 12 in systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline to Day 4, Day 8 and Day 12 in haematology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average Depression Symptom Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Ventricular Lactate Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Copanlisib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration vs. Time Curve From Zero to Infinity (AUC) of Copanlisib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of Copanlisib in Plasma Over the Time Interval From 0 to 168 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in K-BDEFS
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in K-Vineland-II
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in CISA-2
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in CFI
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Concentrations of total 14C radioactivity and AZD2171 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of total radioactivity in urine and faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of cancer-related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Lumbar Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Width resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who remain failure-free
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients with Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pseudomonas Aeruginosa Density in Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of valsartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Sleep Related Events Per Hour
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of microcephaly
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of microcephaly attributable to ZIKV
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of microcephaly linked to other infectious etiologies
Endpoint domain: Mortality/survival
Primary endpoint: Change in Roland Moris Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: incidence of severe adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Dropout
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment Emergent Symptom Scale (TESS)
Endpoint domain: Adverse events/effects
Primary endpoint: complications of COVID-19 infection on rare skin diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: potential comorbidity factors related to COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impact on the management of chronic conditions (change in treatment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma Nicotine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coping with Discrimination
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Sitting Without Support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar lavage concentrations of interleukin-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensory Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid bio markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of ctDNA analysis for RAS mutation analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal Cancer Incidence
Endpoint domain: Mortality/survival
Primary endpoint: ADHD Symptoms Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma IGF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Type-specific Vaccine Virus Shedding
Endpoint domain: Adverse events/effects
Primary endpoint: Change in eye gaze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of Withdrawal measured by Subjective Opioid Withdrawal Scale (SOWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of Withdrawal measured by Clinician-Rated Opioid Withdrawal Scale (COWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in co-morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of tissue HRR-related gene mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Cardiac Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Develop at Least a 4-fold or 2.5- Fold Increase in Anti-Human Epidermal Growth Factor Receptor (HER2)/Neu Antibody Dilution Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: early postoperative cardiac complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in micturition frequency per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in urinary urge incontinence (UUI) episodes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area Under the Serum Concentration vs. Time Profile (AUC72h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childbirth Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Marital Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of subjects reporting headache pain freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with absence of Most Bothersome Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progression of chronic renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of Gamma-Glutamyl Transpeptidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit of NRX 194204
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes